Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
AssigneeAlliance Pharmaceutical Corp.
InventorDavid M. Long, Jr.
Life of this patent
Estimating the term…
Abstract
Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.
Claims25
A method for the parenteral administration of a fluorocarbon emulsion comprising the steps of:
- administering prophylactically to a mammal in need of said emulsion, an anti-inflammatory drug in an amount sufficient to oppose the transient adverse (TAPR) response thereto;
- and
- administering said emulsion parenterally to said mammal,
- whereby said transient adverse physiological (TAPR) response is prevented or attenuated.
An improvement in a method for parenteral administration of a fluorocarbon emulsion to a mammal in need thereof, wherein the improvement comprises a prophylactic administration of an effective amount of a TAPR-preventing or TAPR-opposing anti-inflammatory drug, wherein the anti-inflammatory drug is administered to the mammal before administration of the fluorocarbon emulsion.
A method for the parenteral administration of a fluorocarbon emulsion to a patient in need thereof, comprising in conjunction with said parenteral administration, prophylaxis with an effective anti-inflammatory dose of a drug which acts to oppose the transient adverse physiological (TAPR) response of said patient to said emulsion.
A fluorocarbon emulsion comprising an effective amount of a TAPR-preventing or TAPR-opposing drug selected from the group consisting of steroidal and non-steroidal anti-inflammatory agents, anti-pyretic agents, and non-narcotic analgesic agents.
An improvement in a method for parenteral administration of a fluorocarbon emulsion to a mammal in need thereof, wherein the improvement comprises administration of an effective amount of a TAPR-preventing or TAPR-opposing anti-inflammatory drug, wherein the anti-inflammatory drug is administered to the mammal before and concurrently with administration of the fluorocarbon emulsion.
Dependencies are inferred from the claim text.